ClinicalTrials.gg
Drug

BLU-5937 clinical trials

Also written Camlipixant and BLU-5937.

studies test it
16
open now
2
in phase 3
3
first study started
2018

How each study uses BLU-5937 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the BLU-5937 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

BLU-5937
8
GSK5464714
1

Other names

Camlipixant
9

Studies by the year they started

16 studies that test it; most in 2020 (3)

Studies that test BLU-5937, by start year
YearStudies
20181
20191
20203
20211
20223
20232
20242
20251
20262

By phase

A phase 1/2 study counts in both.

Phase 1
9
Phase 2
4
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 0

Bellus Health Inc. - a GSK company (13) · GlaxoSmithKline (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test BLU-5937, phase 3 first.

Studies

Open first, then newest update. How each study uses BLU-5937 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

Codes

What other systems call BLU-5937 · ClinicalTrials.gg INT001270

  • MeSH (NLM) C000657411BLU-5937One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.